Cargando…

Treatment of allosensitized patients receiving allogeneic transplantation

Donor-specific anti-HLA antibodies (DSAs) are a major cause of engraftment failure in patients receiving haploidentical stem cell transplantation (HaploSCT). Effective treatments are needed for these patients, who often have no other donor options and/or are in need to proceed urgently to transplant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciurea, Stefan O., Al Malki, Monzr M., Kongtim, Piyanuch, Zou, Jun, Aung, Fleur M., Rondon, Gabriela, Chen, Julianne, Taniguchi, Michiko, Otoukesh, Salman, Nademanee, Auayporn, Forman, Stephen J., Champlin, Richard, Gendzekhadze, Ketevan, Cao, Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945639/ https://www.ncbi.nlm.nih.gov/pubmed/34474478 http://dx.doi.org/10.1182/bloodadvances.2021004862

Ejemplares similares

Protective Effect of HLA-DPB1 Mismatch Remains Valid in Reduced-Intensity Conditioning Unrelated Donor Hematopoietic Cell Transplantation
por: Malki, Monzr M. Al, et al.
Publicado: (2019)

Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era
por: Yeh, Jason, et al.
Publicado: (2021)

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL
por: Aldoss, Ibrahim, et al.
Publicado: (2022)

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma
por: Herrera, Alex F., et al.
Publicado: (2021)

Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation
por: Kongtim, Piyanuch, et al.
Publicado: (2016)

Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections
por: Ramdial, Jeremy L., et al.
Publicado: (2021)

An Unusual Presentation of Nocardiosis in an Allogeneic Transplant Recipient
por: Ibrahim, Uroosa, et al.
Publicado: (2016)

Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study
por: La Rosa, Corinna, et al.
Publicado: (2023)

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis
por: Gooptu, Mahasweta, et al.
Publicado: (2022)

Type 1 interferon to prevent leukemia relapse after allogeneic transplantation
por: Magenau, John M., et al.
Publicado: (2021)

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
por: Maurer, Katie, et al.
Publicado: (2021)

Antibody-dependent cellular cytotoxicity by allosensitized human T cells
Publicado: (1978)

Genetic associations with immune-mediated outcomes after allogeneic hematopoietic cell transplantation
por: Martin, Paul J., et al.
Publicado: (2022)

EASIX-1year and late mortality after allogeneic stem cell transplantation
por: Kordelas, Lambros, et al.
Publicado: (2023)

Allogeneic T cells cause acute renal injury after hematopoietic cell transplantation
por: Miyata, Masahiro, et al.
Publicado: (2023)

Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy
por: Chiesa, Robert, et al.
Publicado: (2022)

Antithymocyte globulin exposure in CD34(+) T-cell–depleted allogeneic hematopoietic cell transplantation
por: Lakkaraja, Madhavi, et al.
Publicado: (2022)

Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft Function
por: Arslan Davulcu, Eren, et al.
Publicado: (2023)

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study
por: Achini-Gutzwiller, Federica R., et al.
Publicado: (2023)

Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades
por: Nishiwaki, Satoshi, et al.
Publicado: (2022)

Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant
por: Pérez-Valencia, Amanda Isabel, et al.
Publicado: (2022)

Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic
por: Devine, Steven M., et al.
Publicado: (2023)

Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation
por: Kanaan, Sami B., et al.
Publicado: (2023)

Human herpesvirus 6–specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients
por: Noviello, Maddalena, et al.
Publicado: (2023)

Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
por: Murthy, Hemant S., et al.
Publicado: (2023)

Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant
por: Rubinstein, Jeremy D., et al.
Publicado: (2022)

Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation
por: Ren, Xiying, et al.
Publicado: (2021)

Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects
por: Patterson, Michael T., et al.
Publicado: (2023)

Donor bone marrow–derived macrophage engraftment into the central nervous system of patients following allogeneic transplantion
por: Loeb, Anisha M., et al.
Publicado: (2023)

Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children
por: Masetti, Riccardo, et al.
Publicado: (2023)

CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia
por: Akahoshi, Yu, et al.
Publicado: (2023)

Variable CD34(+) recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic
por: Purtill, Duncan, et al.
Publicado: (2020)

Megadose (90)Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma
por: Chow, Victor A., et al.
Publicado: (2021)

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission
por: Jentzsch, Madlen, et al.
Publicado: (2022)

The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients
por: Sourisseau, Mathilde, et al.
Publicado: (2022)

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning
por: Iwasaki, Makoto, et al.
Publicado: (2022)

Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use
por: Weber, Daniela, et al.
Publicado: (2022)

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
por: Tamari, Roni, et al.
Publicado: (2023)

Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning
por: Townsend, William M, et al.
Publicado: (2013)

Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplant: SARS-CoV-2 Vaccine as a Potential Trigger
por: Azem, Amin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q9imk36m7kr6l73168u10nmbqp